Skip to content

LOXL1 Polymorphism in Pseudoexfoliation Syndrome

Evaluation of LOXL1 Polymorphism in Pseudoexfoliation Syndrome in the Korean Population

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01515735
Enrollment
60
Registered
2012-01-24
Start date
2011-12-31
Completion date
2012-12-31
Last updated
2012-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pseudoexfoliation Syndrome

Brief summary

To evaluate the association profiles of the lysyl oxidase-like 1 gene polymorphisms with pseudoexfoliation syndrome in the Korean population, Genotypes of lysyl oxidase-like 1 gene were analyzed by direct sequencing.

Detailed description

To evaluate the association profiles of the lysyl oxidase-like 1 gene polymorphisms with pseudoexfoliation syndrome in the Korean population, peripheral blood sampling will be done from the patients with pseudoexfoliation. And genotypes of the three single nucleotide polymorphisms of lysyl oxidase-like 1 gene , rs1048661, rs3825942, rs2165241 were analyzed by direct sequencing.

Interventions

None listed

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of Pseudoexfoliation

Exclusion criteria

* medical condition that peripheral blood sampling cannot be done

Design outcomes

Primary

MeasureTime frameDescription
Genotypes of the three single nucleotide polymorphisms of LOXL1 (rs1048661, rs3825942, rs2165241)about 1 year (when all patients were recruited)Genotypes of the three single nucleotide polymorphisms of LOXL1 were analyzed by direct sequencing, after obtained from the peripheral blood sampling from patients.

Countries

South Korea

Contacts

Primary ContactChangwon Kee, M.D., Ph.D.
ckee@skku.edu82-2-3410-3564

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026